4/30
12:11 pm
mck
Earnings Preview: McKesson (MCK) Q4 Earnings Expected to Decline [Yahoo! Finance]
Low
Report
Earnings Preview: McKesson (MCK) Q4 Earnings Expected to Decline [Yahoo! Finance]
4/30
11:10 am
mck
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Citigroup Inc. from $575.00 to $620.00. They now have a "buy" rating on the stock.
Low
Report
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Citigroup Inc. from $575.00 to $620.00. They now have a "buy" rating on the stock.
4/30
04:45 am
mck
McKesson: Time To Get More Cautious [Seeking Alpha]
Low
Report
McKesson: Time To Get More Cautious [Seeking Alpha]
4/28
08:24 am
mck
Institutional investors are McKesson Corporation's (NYSE:MCK) biggest bettors and were rewarded after last week's US$2.4b market cap gain [Yahoo! Finance]
Low
Report
Institutional investors are McKesson Corporation's (NYSE:MCK) biggest bettors and were rewarded after last week's US$2.4b market cap gain [Yahoo! Finance]
4/26
08:03 pm
mck
McKesson (MCK) Rises But Trails Market: What Investors Should Know [Yahoo! Finance]
Low
Report
McKesson (MCK) Rises But Trails Market: What Investors Should Know [Yahoo! Finance]
4/26
11:59 am
mck
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
4/25
11:07 pm
mck
McKesson Co. (NYSE: MCK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
McKesson Co. (NYSE: MCK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
4/25
09:19 am
mck
Ontada Names Jade Cusick Chief Commercial Officer [Yahoo! Finance]
Low
Report
Ontada Names Jade Cusick Chief Commercial Officer [Yahoo! Finance]
4/25
08:21 am
mck
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua
Low
Report
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua
4/24
08:00 am
mck
McKesson Corporation Declares Quarterly Dividend
Low
Report
McKesson Corporation Declares Quarterly Dividend
4/23
07:04 am
mck
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma [Yahoo! Finance]
Low
Report
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma [Yahoo! Finance]
4/22
04:37 pm
mck
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting [Yahoo! Finance]
Low
Report
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting [Yahoo! Finance]
4/22
04:14 am
mck
Medical Billing Outsourcing Market to USD 41.9Bn by 2032, says Global Market Insights Inc. [Yahoo! Finance]
Low
Report
Medical Billing Outsourcing Market to USD 41.9Bn by 2032, says Global Market Insights Inc. [Yahoo! Finance]
4/15
01:18 pm
mck
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Morgan Stanley from $522.00 to $548.00. They now have an "overweight" rating on the stock.
Low
Report
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Morgan Stanley from $522.00 to $548.00. They now have an "overweight" rating on the stock.
4/10
12:05 pm
mck
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Argus from $510.00 to $570.00. They now have a "buy" rating on the stock.
Low
Report
McKesson Co. (NYSE: MCK) had its price target raised by analysts at Argus from $510.00 to $570.00. They now have a "buy" rating on the stock.
4/8
08:14 am
mck
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting [Yahoo! Finance]
Low
Report
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting [Yahoo! Finance]
4/3
11:24 am
mck
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
4/2
09:29 am
mck
McKesson Launches Project Oasis to Address Pharmacy Deserts in Underserved Communities [Yahoo! Finance]
Low
Report
McKesson Launches Project Oasis to Address Pharmacy Deserts in Underserved Communities [Yahoo! Finance]
3/30
07:26 pm
mck
Top 10 Fastest Growing Cities in Texas [Yahoo! Finance]
Low
Report
Top 10 Fastest Growing Cities in Texas [Yahoo! Finance]
3/29
08:16 am
mck
With 88% institutional ownership, McKesson Corporation (NYSE:MCK) is a favorite amongst the big guns [Yahoo! Finance]
Low
Report
With 88% institutional ownership, McKesson Corporation (NYSE:MCK) is a favorite amongst the big guns [Yahoo! Finance]
3/27
04:10 pm
mck
McKesson Corporation Announces Fourth Quarter Fiscal 2024 Earnings Release Date
Low
Report
McKesson Corporation Announces Fourth Quarter Fiscal 2024 Earnings Release Date
3/26
10:58 am
mck
UPDATE 1-Rite Aid reaches bankruptcy settlement with lenders, DOJ, McKesson [Yahoo! Finance]
Low
Report
UPDATE 1-Rite Aid reaches bankruptcy settlement with lenders, DOJ, McKesson [Yahoo! Finance]
3/26
10:54 am
mck
Rite Aid reaches bankruptcy settlement with lenders, DOJ, McKesson [Reuters]
Low
Report
Rite Aid reaches bankruptcy settlement with lenders, DOJ, McKesson [Reuters]
3/26
10:23 am
mck
Rite Aid reaches bankruptcy settlement with lenders, DOJ, McKesson [Yahoo! Finance]
Low
Report
Rite Aid reaches bankruptcy settlement with lenders, DOJ, McKesson [Yahoo! Finance]
3/25
01:36 pm
mck
US Healthcare Information Exchange Market Outlook 2024-2029 - Federated Healthcare Model Dominates Market Share, Expected to Surge with Rising Digital Adoption and Investment [Yahoo! Finance]
Low
Report
US Healthcare Information Exchange Market Outlook 2024-2029 - Federated Healthcare Model Dominates Market Share, Expected to Surge with Rising Digital Adoption and Investment [Yahoo! Finance]